• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
View
View

... applications.Development of hybridoma for monoclonal antibodies. Study of drugs produced by biotechnology such as Activase, Humulin, Humatrope, HB etc. Antibiotics: Historical development of antibiotics. Antimicrobial spectrum and methods used for their standardization. Screening of soil for organis ...
Sympathetic Drugs
Sympathetic Drugs

... Adrenoceptor Antagonists α-Blockers • Decr artiolar and venous tone  decr peripheral resistance  hypotension. • Reverse the pressor effects of Epi, because its β2mediated vasodilator effects are unopposed by αmediated vasoconstriction  peripheral resistance falls (Epi reversal). • Cause reflex t ...
Syllabus for GPAT - 2013 PHARMACEUTICS
Syllabus for GPAT - 2013 PHARMACEUTICS

... applications.Development of hybridoma for monoclonal antibodies. Study of drugs produced by biotechnology such as Activase, Humulin, Humatrope, HB etc. Antibiotics: Historical development of antibiotics. Antimicrobial spectrum and methods used for their standardization. Screening of soil for organis ...
Cardiac Drugs Part II
Cardiac Drugs Part II

... High correlation between Coronary Artery Disease (CAD) and high LDL and low HDL. ...
Pharmacology Basics
Pharmacology Basics

... The user is able to break down and/or excrete the drug more quickly due to repeated exposure. Increased excretion ...
Outline
Outline

...  depends on (1) degree of ionization – many and are taken at the same time. Isoniazid can drugs are weak acids/bases. block VitB6 or vice versa. This reduces the o Note that the non-ionized form will pass the efficacy of the drug. This can be solved through membrane. Ionized forms will have less ti ...
Drug İnteractions
Drug İnteractions

... the effectiveness of one or both. For example, nonsteroidal antiinflammatory drugs (NSAIDs—see Pain: Nonsteroidal AntiInflammatory Drugs), such as ibuprofen , which are taken to relieve pain, may cause the body to retain salt and fluid. Diuretics, such as hydrochlorothiazide and furosemide, help rid ...
ABC`s of Drug Testing
ABC`s of Drug Testing

... ▫ Head hair:  1 cm represents  ...
pre-IND status inhaled INV102
pre-IND status inhaled INV102

... Recent interim data from a Phase 2 trial of oral nadolol in smoking cessation was highly encouraging, demonstrating the compound’s efficacy on four key biomarkers associated with lung inflammation. The global market opportunity for new treatments for these diseases is in excess of $35 billion. Invio ...
TEMSIS
TEMSIS

... Schedule lV: Less abuse potential then lll, limited psychological and/or physical dependence ...
Drug Interactions
Drug Interactions

... Terfenidine removed from the market after several deaths ...
FORM – Initial Review - UIC Office of the Vice Chancellor for Research
FORM – Initial Review - UIC Office of the Vice Chancellor for Research

... storage, limiting access to individuals listed as study personnel on the protocol , dispensing, and accountability. 2. Indicate where the drug will be stored. 3. Provide a contact person at the site who can verify the institution’s approval of these ...
Drug interaction of plasma protein binding
Drug interaction of plasma protein binding

... Adverse reactions Dangerous factors: ...
Basic pharmacology
Basic pharmacology

... #Phase II(safety & efficacy in Small population) #Phase III (safety & efficacy in large population) #Phase IV (Post-marketing Study, safety in special population & new indication) ...
ELIMINATION OF DRUGS
ELIMINATION OF DRUGS

... lipidotropic activity; hydroxyl, amino-group – high ionization, high hydrophilic properties, weak penetration through the membranes • Fluoric atom in molecules of GCS, neuroleptics increases their ...
Nuplazid ™ - Pimavanserin Manufacturer
Nuplazid ™ - Pimavanserin Manufacturer

... Score ...
Herbal Herbal Highs
Herbal Herbal Highs

... drugs have raised international concerns over the availability and legality of such recreational drugs. In 2002, the U.S. was one of the first countries to ban BZP, classifying it as a schedule 1 controlled substance. Since then, BZPs have been banned in Australia, Greece, Italy, Malta, Denmark, Swe ...
NEWER ANTIEPLEPTICS CENTRALLY ACTING MUSCLE
NEWER ANTIEPLEPTICS CENTRALLY ACTING MUSCLE

... saturability, which means that increasing the dose does not proportionately increase the amount absorbed. This makes gabapentin relatively safe and free of side effects associated with overdosing. ...
1 Top Pediatric Medications Common Pediatric
1 Top Pediatric Medications Common Pediatric

... Ń Is generally faster than normal adult levels until age 2, then slowly declines until puberty, and finally drops to normal adult levels. Ń This may mean increased dosage or dosing frequency for drugs eliminated by hepatic metabolism. ...
Answer Key of MCQ of AMO Exam
Answer Key of MCQ of AMO Exam

... 1. Total 110 multiple choice questions are provided out of which any 80 questions will have to be answered. Each question carries one mark. 2. No provision of negative marking. 3. Total 07 short answer questions (to be answered maximum in 75 words) out of which any 04 Questions will have to be answe ...
CAL packages
CAL packages

... This module normally comprises 64 hours of lectures, 40 hours of practicals/seminars/laboratory classes, 208 hours of guided study that will include case-based learning and experiential learning. Blood: overview of the structure and functions of blood. Principles of blood grouping and blood transfus ...
LACHMAN CONSULTANT SERVICES, INC.
LACHMAN CONSULTANT SERVICES, INC.

... The proposed package insert for the Dextroamphetamine Sulfate Tablets USP, 2.5 mg, 7.5 mg, 15 mg, 20 mg and 30 mg is consistent with the reference-listed drug labeling . These strengths are within the treatment ranges described in the reference-listed drug labeling and are clearly contemplated doses ...
Sheet#6,Dr.Alia,Marwh Nsour
Sheet#6,Dr.Alia,Marwh Nsour

... Now , as a dentist when we deal with patient at our chair . FIRSTLY ,we must take a good medical history , so if your patient in past is on a corticosteroid therapy at least for 2 weeks and he stop it before coming to ur clinic by 1-2 years , discontinuous it ,or he still in corticosteroid therapy , ...
Drug Products That Have Been Withdrawn from the US Market
Drug Products That Have Been Withdrawn from the US Market

... Drug Products That Have Been Withdrawn from the U.S. Market Since 2000, the U.S. Food and Drug Administration has approved nearly 300 new drug applications and biologics license applications for new molecular entities. In the same time period, a few new drugs were withdrawn from the market by the ma ...
CH 6 High Risk Populations - J. de Hoon
CH 6 High Risk Populations - J. de Hoon

... No experiments where death or injury is expected, ecept when physician is also at risk 10 basic principles -> basis of curent guidelines and regulations - 1961: Thalidomide disaster - 1962: Kefhauver-Harris amendment: IND file needs to be present before going to humans: Protocol, safety data, effica ...
< 1 ... 105 106 107 108 109 110 111 112 113 ... 161 >

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication ""The Economic Power of Orphan Drugs"", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act (ODA) 1983 and similar Acts in other regions of the world and also driven by ""high-profile philanthropic funding."" The period between 2001 to 2011 was the ""most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals."" For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an ""impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs."" By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs, Thomson Reuters.By 2012, ""the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.""
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report